reason report
bottom line op rate predic view
long-term orient investor believ turnaround stori
make new leadership focu
lead posit across key ortho mkt trade signific
p/ discount large-cap med-tech view alreadi
price potenti downward estim revis despit
lower estim pt inch vs base
ep slightli higher rel expand grp multipl
organ sale growth beat in-lin adj ep
posit especi follow number expect
result past qtr bigger focu though
outlook offici guidanc provid bryan
hanson take busi suppli issu
first quarter ceo overal think mr hanson offer candid
view suppli situat echo suspect
might hear estim timelin fix suppli issu
carri inher risk unpredict quick fix
increas spend necessari lead lower ep
vs consensu posit note ceo hanson express
confid revenue growth re-acceler prospect -- albeit
pace improv may bit slower previous thought
consensu expect outlook call
cc revenue growth report revenu rang
plu ep rang top line assum vs
slowdown key ortho market season uk elect
procedur delay less robust apac sale strong
repeat fx tailwind sell day
headwind management expect product output warsaw north
campu least level encourag view
meanwhil gm project toward lower end
bracket estimate consensu turn ep
consensu vs consensu
sales/ep guidanc rang captur prior estim upper
end new sales/ep closer midpoint guidanc
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
cash ep
compani inform leerink partner llc research
million ep ex-amort
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
revenue growth management expect gradual improv revenue growth
throughout driven normal bill day neg
impact revers impact full-year basi
lesser extent new product contribut robot knee launch
later
gm rang full year serv
signific headwind vs management expect
normal co anniversari north campu
varianc opex perspect management note continu
reinvest drive top-lin growth requir stepped-up invest
-- larg -- ensur fast resolut suppli
issu possibl well management expect y/i expens headwind
non-sal forc bonus paid
major record sg effect tax rate expect
rang incr tax benefit reinvest
biz vs flow bottom line overal think ceo hanson
take conserv approach reset expect restor
investor confid compani abil execut
remedi new product project organ
cc revenue growth would reflect acceler
model growth progress acceler low point
reach acceler
ep reflect lower gm assumpt lower full-
year sale addit higher level sg spend bring
forecast vs prior continu pursu dual sourc
strategi goal go offens
management acknowledg could take time fulli earn back trust
custom sale rep secur new busi henc
slower anticip recoveri return market rate push
new product keep eye mid-to-l time-frame
rosa us total knee applic ltd launch
cementless persona knee ltd launch full launch
hip/kne came better expect acceler
y/i vs base result well
op op pre-announce result look like us hip/kne
market step touch vs hip/kne growth
possibl aid hurrican deferr impact total compani
price got touch wors hip/
knee deriv sourc india australia
china management also note touch pressur us management
expect level price pressur continu without
abil off-set price normal product improv
cog given suppli issu contribut slightli pressur
gm outlook emphasi lower end vs management prior
rate zimmer hold nyse outperform pt view strong
turnaround stori make end day gener solid hold
market-lead posit across key orthoped market favor demograph tailwind
trade signific price-to-earnings discount large-cap med-tech view alreadi
price potenti downward estim revis larg extent think
new perman ceo place compani gradual begin move past
suppli issu -- -lead consist top-lin growth re-acceler -- -the stock steep discount
vs peer narrow
trade fairli steep discount large-cap med-tech group forward price-to-earnings average
believ level discount vs large-cap peer warrant given average top-
line growth execut risk relat zbh-biomet integr suppli issu think
current discount vs peer wide believ ultim busi
time capabl gener hsd low double-digit ep growth gradual
top-lin acceler low-to-mid singl digit growth territori pt assum
trade ep narrow valuat gap vs large-
cap med-tech average would current price-to-earnings multipl would still
repres discount large-cap exclud ew forward
group average price-to-earnings compani large-cap group includ
risk valuat includ abl execut post-biomet ldrh deal
synergi guidanc biomet relat sale forc disrupt materi greater
degre assum -- -which ultim could put achiev synergi guidanc target
risk take longer address suppli issu build safeti stock inventori -- -which
could limit co abil meet demand and/or regain market share futur qtr crucial
sale growth acceler stori underli ortho recon growth rate slow vs current
expect level price eros industri ortho recon price occur dramat
pace expect wors steadi y/i declin rang unabl
off-set asp price declin posit mix benefit relat new product offer
could hinder long-term share price appreci robot total knee categori
begin acceler faster-than-expect and/or abl commerci large-joint
dedic robot platform time fashion
million except ep
compani report streetaccount consensu leerink partner llc research
million except ep
compani report leerink partner llc estim
like lower
end rang
sg sale
 sale
favor foreign exchang impact
less sell day neg impact
management expect headwind revers
full year net bill day impact
management expect slightl improv subsequ
signific headwind vs
expect normal
y/i expens headwind non-sal forc
full year adj effect tax rate rang
management plan reinvest tax save biz
ep adjust item
compani report leerink partner llc estim
management goal alloc co
toward debt repay
dollar million except per share data
product sold ex-intang amort
research develop expens
sell gener administr expens
income/ loss attribut non-controlling
adj dilut averag share million
gross margin ex devic tax
oper expens sale
sg sale
 sale
compani data leerink partner llc estim
dollar million
total sale unadjust divestitur
total sale adjust
y/i growth pro-forma adjust cc day ex-ldr
dollar million
compani report leerink partner estim
